Sugi Predict

Sugi Predict / Targets / IL17A

IL17A

Interleukin-17A · Q16552 · IL17A on Sugi Atlas →

14,251 patent compounds predicted against IL17A, 5,374 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL17843267 SCHEMBL17843267 0.83 7/20
SCHEMBL17843342 SCHEMBL17843342 0.64 7/20
SCHEMBL17843289 SCHEMBL17843289 1.00 6/20
SCHEMBL17843307 SCHEMBL17843307 1.00 6/20
SCHEMBL17843288 SCHEMBL17843288 0.85 6/20
SCHEMBL17843297 SCHEMBL17843297 0.84 6/20
SCHEMBL17843272 SCHEMBL17843272 0.82 6/20
SCHEMBL17843331 SCHEMBL17843331 0.76 6/20
SCHEMBL17843340 SCHEMBL17843340 0.75 6/20
SCHEMBL17843312 SCHEMBL17843312 0.70 6/20
SCHEMBL17843265 SCHEMBL17843265 1.00 5/20
SCHEMBL17843266 SCHEMBL17843266 0.75 5/20
SCHEMBL17843319 SCHEMBL17843319 0.71 5/20
SCHEMBL17843298 SCHEMBL17843298 0.71 5/20
SCHEMBL17843269 SCHEMBL17843269 0.70 5/20
SCHEMBL17843335 SCHEMBL17843335 0.69 5/20
SCHEMBL17843336 SCHEMBL17843336 0.69 5/20
SCHEMBL17843338 SCHEMBL17843338 0.62 5/20
SCHEMBL17843282 SCHEMBL17843282 0.52 5/20
SCHEMBL15353139 SCHEMBL15353139 0.49 5/20

Clinical trials — most relevant to IL17A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT). PHASE4UNKNOWN
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission PHASE4ACTIVE_NOT_RECRUITING
PsA Secukinumab XCT Structural Progression Study PHASE4COMPLETED
Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies PHASE4COMPLETED
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions PHASE4COMPLETED
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) PHASE3COMPLETED
A Study to Evaluate the Efficacy and Safety of LZM012 PHASE3UNKNOWN
Anti-IL-17 a New Treatment for Contact Dermatititis PHASE3UNKNOWN
Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo. PHASE3COMPLETED
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa PHASE3RECRUITING
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis PHASE3COMPLETED
Mechanistic Study of Indigo Naturalis in Treating Psoriasis PHASE2COMPLETED
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis PHASE1RECRUITING
A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis PHASE1COMPLETED
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa nanRECRUITING
Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis nanCOMPLETED
Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients nanCOMPLETED
Relation of IL23R and IL17A Gene Polymorphisms Plus Serum Levels of IL23 and IL17A to Rheumatoid Arthritis Susceptibility and Activity nanNOT_YET_RECRUITING
Evaluation of Aqueous Humor DEL-1 and IL-17 Levels in Diabetic Cataract Patients nanRECRUITING
Effect of Smoking and Periodontal Therapy on Salivary and Gingival Crevicular IL-17 and IL-35 nanCOMPLETED
Dietary Approach to Mild-to-moderate Psoriasis nanRECRUITING
Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17 nanCOMPLETED
Ankylosing Spondylitis nanNOT_YET_RECRUITING
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
The Role of Serum Cytokines IL_17 A and IL_10 in Disease Activity of Acute B Lymphoblastic Leukemia in South Egypt nanNOT_YET_RECRUITING
Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis nanRECRUITING
Serum Interleukin - 17A in Juvenile Idiopathic Arthritis nanUNKNOWN
Involvement of Pollutants in Atopic Dermatitis and Psoriasis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a IL17A binder may also engage these)

ProteinNameSimilarity
Q60I29 — 0.999 Q60I29 →
O40633 — 0.996 O40633 →
Q5BJ95 — 0.995 Q5BJ95 →
Q61453 — 0.994 Q61453 →
Q687Y7 — 0.993 Q687Y7 →
P24916 — 0.993 P24916 →
Q62386 — 0.988 Q62386 →
Q7TNI7 — 0.986 Q7TNI7 →
Q96PD4 — 0.984 Q96PD4 →
A6N6I9 — 0.983 A6N6I9 →
Q8VHH8 — 0.977 Q8VHH8 →
Q9UHF5 — 0.977 Q9UHF5 →
Q8SPN5 — 0.975 Q8SPN5 →
P13698 — 0.975 P13698 →
Q8SQ09 — 0.975 Q8SQ09 →
Q9PTQ2 — 0.974 Q9PTQ2 →
O46532 — 0.974 O46532 →
Q9H293 — 0.974 Q9H293 →
P00683 — 0.973 P00683 →
O46526 — 0.973 O46526 →
P61822 — 0.973 P61822 →
Q9WUX4 — 0.973 Q9WUX4 →
PDGFA Platelet-derived growth factor subunit A 0.973 landscape →
Q9QXT6 — 0.972 Q9QXT6 →
Q8SQ07 — 0.972 Q8SQ07 →
P30970 — 0.972 P30970 →
Q91119 — 0.972 Q91119 →
P00680 — 0.972 P00680 →
Q9QYX3 — 0.972 Q9QYX3 →
P08904 — 0.971 P08904 →